Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urethral Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 18Cisplatin 14Paclitaxel 9Vinblastine 7Methotrexate 7Radiotherapy 6Doxorubicin 6Carboplatin 6Fluorouracil 4Surgical Procedures, Operative 3Mitomycin 3Filgrastim 3BCG Vaccine 3Gefitinib 2Docetaxel 2Cystectomy 2valrubicin 1rubitecan 1romidepsin 1piritrexim 1merphos 1lonafarnib 1durvalumab 1avelumab 1atezolizumab 1Watchful Waiting 1Urination 1Transurethral Resection of Bladder 1Taxes 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Urinary Bladder Neoplasms × Gefitinib × Clear all
NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Canadian Cancer Trials Group

Phase 3 Terminated
41 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00014144 2012-10-08

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

SWOG Cancer Research Network

Phase 2 Completed
31 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡